Dietary Modulation of Inflammation-Induced Colorectal Cancer through PPAR
Open Access
- 1 January 2009
- journal article
- review article
- Published by Hindawi Limited in PPAR Research
- Vol. 2009, 1-9
- https://doi.org/10.1155/2009/498352
Abstract
Mounting evidence suggests that the risk of developing colorectal cancer (CRC) is dramatically increased for patients with chronic inflammatory diseases. For instance, patients with Crohn's Disease (CD) or Ulcerative Colitis (UC) have a 12–20% increased risk for developing CRC. Preventive strategies utilizing nontoxic natural compounds that modulate immune responses could be successful in the suppression of inflammation-driven colorectal cancer in high-risk groups. The increase of peroxisome proliferator-activated receptor-(PPAR-) expression and its transcriptional activity has been identified as a target for anti-inflammatory efforts, and the suppression of inflammation-driven colon cancer. PPARdown-modulates inflammation and elicits antiproliferative and proapoptotic actions in epithelial cells. All of which may decrease the risk for inflammation-induced CRC. This review will focus on the use of orally active, naturally occurring chemopreventive approaches against inflammation-induced CRC that target PPARand therefore down-modulate inflammation.
Keywords
Funding Information
- National Center for Complementary and Alternative Medicine (5R01AT4308)
This publication has 90 references indexed in Scilit:
- Oral Administration of Blueberry Inhibits Angiogenic Tumor Growth and Enhances Survival of Mice with Endothelial Cell NeoplasmAntioxidants and Redox Signaling, 2009
- Multi-targeted therapy of cancer by omega-3 fatty acidsCancer Letters, 2008
- NF-κB and cancer—identifying targets and mechanismsCurrent Opinion in Genetics & Development, 2008
- Cancer incidence and mortality patterns among specific Asian and Pacific Islander populations in the U.S.Cancer Causes & Control, 2007
- The PPARγ Agonist Rosiglitazone Impairs Colonic Inflammation in Mice with Experimental ColitisJournal of Clinical Immunology, 2007
- How many drug targets are there?Nature Reviews Drug Discovery, 2006
- Resveratrol improves health and survival of mice on a high-calorie dietNature, 2006
- A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γNature, 2005
- ROS stress in cancer cells and therapeutic implicationsDrug Resistance Updates, 2004
- On the Origin of Cancer CellsScience, 1956